Myo-inositol and D-chiro inositol are two forms of the same compound, but they do different things in different tissues. If you are trying to decide between them, the short answer is: most people benefit from both in a specific ratio. The details matter, and getting them wrong can actually work against you.
Quick Comparison
| Property | Myo-Inositol | D-Chiro Inositol |
|---|---|---|
| Abundance in the body | 95%+ of total inositol | Less than 5% |
| Primary tissue role | Ovaries, brain, reproductive tissue | Muscle, liver, glycogen storage |
| Key function | Follicle development, FSH signaling | Insulin-mediated glycogen synthesis |
| Standard dose | 4,000 mg/day | 100 mg/day (in 40:1 combo) |
| Best for | Fertility, egg quality, ovarian function | Insulin resistance support |
| Risk of excess | Low at standard doses | Can impair egg quality at high doses |
| Evidence base | Extensive (multiple RCTs) | Moderate (growing) |
What These Two Forms Actually Are
Inositol is a carbocyclic sugar with nine possible structural forms. Two of them matter for supplementation: myo-inositol (MYO) and D-chiro inositol (DCI).
Myo-inositol is the most abundant form in the human body. It makes up over 95% of the total inositol pool and concentrates heavily in ovarian follicular fluid, the brain, and reproductive tissue. At the cellular level, myo-inositol acts as a second messenger in the insulin signaling cascade and plays a direct role in follicle-stimulating hormone (FSH) signaling within the ovaries.
D-chiro inositol is not consumed directly in large amounts from food. The body produces it from myo-inositol through an enzyme called epimerase. DCI concentrates in tissues involved in glycogen storage, particularly skeletal muscle and the liver. Its primary function is mediating the non-oxidative disposal of glucose, meaning it helps cells store glucose as glycogen after an insulin signal.
The ratio between these two forms in healthy human plasma is approximately 40:1, myo to D-chiro. This is not a supplement marketing number. It was established through biochemical measurement and confirmed by an international consensus of researchers (Facchinetti et al., 2015).
How Epimerization Works (and How It Breaks)
The enzyme that converts myo-inositol into D-chiro inositol, epimerase, is activated by insulin. In a healthy body, insulin triggers just enough conversion to supply D-chiro where it is needed (muscle, liver) while preserving myo-inositol where it is needed (ovaries, brain).
In women with polycystic ovary syndrome (PCOS), this system breaks down. Insulin resistance causes chronically high insulin levels, which overstimulates the epimerase enzyme. The result: too much myo-inositol gets converted to D-chiro in certain tissues, depleting the myo-inositol supply that ovarian follicles depend on.
This creates a paradox. Women with PCOS often have excess D-chiro inositol in ovarian tissue and a deficit of myo-inositol, the exact opposite of what follicles need to mature normally. Research by Laganà et al. (2018) describes this pathophysiology in detail, connecting the inositol imbalance to impaired follicle development, anovulation, and reduced oocyte quality.
Myo-Inositol: What the Research Shows
Myo-inositol has the larger and more mature evidence base of the two forms, particularly for reproductive outcomes.
Ovulation and menstrual regularity. Multiple randomized controlled trials show that myo-inositol supplementation at 4,000 mg/day restores spontaneous ovulation in 40-60% of previously anovulatory women with PCOS within 12-16 weeks. It also normalizes the LH/FSH ratio, a hormonal marker that is frequently high in PCOS.
Egg quality in IVF. For women undergoing fertility treatment, myo-inositol supplementation before ovarian stimulation improves oocyte quality and reduces the amount of gonadotropin medication needed. A systematic review and meta-analysis by Bhide, Pundir et al. (2019) examined the effect of myo-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI and found measurable improvements.
Insulin sensitivity. Myo-inositol reduces fasting insulin, lowers HOMA-IR scores, and increases sex hormone binding globulin (SHBG), which helps reduce the androgenic burden that drives acne, hirsutism, and hair thinning in PCOS.
Testosterone reduction. Studies consistently show 25-40% reductions in free and total testosterone in women using myo-inositol protocols, making it one of the more effective nutritional approaches for hyperandrogenism.
For a full deep dive on this topic, see our Inositol for PCOS guide.
D-Chiro Inositol: What the Research Shows
D-chiro inositol’s evidence base is smaller but growing. Its mechanisms are distinct from myo-inositol.
Insulin signaling. DCI acts as a mediator of insulin action specifically in glycogen synthesis pathways. Research dating back to Larner et al. (2003) identified D-chiro inositol-containing molecules as putative insulin mediators that promote glucose uptake and glycogen storage.
Metabolic improvement in PCOS. When combined with myo-inositol at the 40:1 ratio, DCI contributes to greater metabolic improvements than myo-inositol alone. Nordio and Proietti (2012) found that the combined 40:1 formula reduced BMI, improved insulin resistance markers, and lowered androgens more effectively than myo-inositol by itself.
The ovarian caution. This is where the story gets complicated. DCI does not belong in high concentrations in ovarian tissue. In the ovaries, myo-inositol is the dominant and functional form. Supplementing D-chiro alone at high doses can paradoxically worsen egg quality by mimicking the same myo-inositol depletion that PCOS causes naturally.
Animal research by Bevilacqua et al. (2021) demonstrated that high-dose D-chiro inositol alone induced a PCOS-like syndrome in mouse ovaries. In human studies, Ravanos et al. (2017) found that excess D-chiro inositol in follicular fluid was associated with reduced blastocyst quality in women undergoing IVF.
This is why DCI should not be taken alone in high doses if fertility is a goal. The 40:1 combination prevents this problem.
The 40:1 Ratio: Why It Is the Standard
The 40:1 protocol, typically 4,000 mg myo-inositol plus 100 mg D-chiro inositol daily, has become the benchmark for inositol supplementation. Here is why.
It mirrors physiology. The 40:1 ratio reflects the actual proportion found in healthy human blood. Supplementing in this ratio preserves the natural distribution rather than overloading one form at the expense of the other.
It outperforms either form alone. Monastra et al. (2017) reviewed the evidence and concluded that the 40:1 combination is effective for restoring both ovarian function and metabolic balance in women with PCOS. The combined approach addresses both the reproductive and metabolic dimensions of the condition simultaneously.
International consensus supports it. The International Consensus Conference on Myo-inositol and D-chiro-inositol in Obstetrics and Gynecology, published by Facchinetti et al. (2015), confirmed the 40:1 ratio as the recommended supplementation protocol. This was not a single research group’s opinion. It was a multi-center, multi-author consensus statement.
Who Should Take Which Form
| Profile | Recommended Protocol | Reason |
|---|---|---|
| PCOS with fertility goals | 40:1 combo (4,000 mg MYO + 100 mg DCI) | Protects egg quality while improving insulin sensitivity |
| PCOS without fertility concerns | 40:1 combo or MYO alone | Both approaches improve hormonal and metabolic markers |
| IVF preparation | MYO alone or 40:1 combo | Prioritizes oocyte quality |
| Insulin resistance (no PCOS) | 40:1 combo or DCI with MYO | Targets glycogen storage pathway alongside MYO benefits |
| Weight management with PCOS | 40:1 combo | Myo-inositol for weight loss covers this topic in depth |
| General wellness | MYO alone (2,000-4,000 mg) | Adequate for non-PCOS populations |
Dosage
Standard 40:1 protocol:
- Myo-inositol: 4,000 mg/day (typically split 2,000 mg twice daily with meals)
- D-chiro inositol: 100 mg/day (typically split 50 mg twice daily)
Myo-inositol alone:
- 4,000 mg/day is the most commonly studied dose
- Some protocols use 2,000 mg/day for general wellness
Timeline to results:
- Insulin markers (fasting insulin, HOMA-IR): 8-12 weeks
- Menstrual regularity and ovulation: 12-16 weeks
- Hormonal changes (testosterone, LH/FSH): 12-16 weeks
Dividing the daily dose into two servings taken with meals reduces the mild GI side effects (nausea, bloating) that some users experience when starting. For detailed dosing protocols, see Inositol Dosage.
Common Mistakes to Avoid
Taking D-chiro alone at high doses for fertility. This can deplete myo-inositol in ovarian tissue and reduce egg quality. If fertility is your goal, myo-inositol must be the primary form.
Using the wrong ratio. Some products use a 1:1 or other non-physiological ratios. The clinical evidence specifically supports 40:1. Check the label math before purchasing.
Expecting results in two weeks. Inositol works through chronic correction of insulin signaling and hormonal balance. It is not a fast-acting supplement. Give it a minimum of 8-12 weeks before evaluating.
Stopping when cycles normalize. Many women discontinue inositol after their cycle returns. The hormonal improvements depend on continued supplementation. Discuss long-term use with your healthcare provider.
FAQ
What is the difference between myo-inositol and D-chiro inositol?
Myo-inositol is the dominant form of inositol in the body, concentrated in ovarian tissue, brain, and reproductive organs. D-chiro inositol is a converted form that concentrates in muscle and liver, where it supports glycogen storage. The body makes D-chiro from myo-inositol through an insulin-activated enzyme. Their functions are complementary but tissue-specific, which is why the ratio between them matters.
Should I take myo-inositol or D-chiro inositol for PCOS?
The evidence supports taking both in a 40:1 ratio. The standard protocol is 4,000 mg myo-inositol plus 100 mg D-chiro inositol daily. This combination outperforms either form alone for both metabolic and reproductive outcomes in PCOS (Monastra et al., 2017).
Can too much D-chiro inositol be harmful?
At high doses taken without adequate myo-inositol, D-chiro can impair oocyte quality by depleting myo-inositol in ovarian follicles. Animal research shows high-dose D-chiro alone can induce ovarian changes resembling PCOS (Bevilacqua et al., 2021). Sticking to the 40:1 ratio avoids this risk.
What is the 40:1 inositol ratio and why does it matter?
The 40:1 ratio reflects the natural proportion of myo-inositol to D-chiro inositol in human blood plasma. An international consensus conference confirmed this as the recommended supplementation ratio for women with PCOS (Facchinetti et al., 2015). It preserves the physiological balance, ensuring each tissue gets the form of inositol it needs.
References
- Facchinetti F, Bizzarri M, Benvenga S, et al. (2015). Results from the International Consensus Conference on Myo-inositol and D-chiro-inositol in Obstetrics and Gynecology. Eur J Obstet Gynecol Reprod Biol.
- Monastra G, Unfer V, Harrath AH, et al. (2017). Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecol Endocrinol.
- Nordio M, Proietti E (2012). The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients. Eur Rev Med Pharmacol Sci.
- Bevilacqua A, Dragotto J, Lucarelli M, et al. (2021). High doses of D-chiro-inositol alone induce a PCO-like syndrome and other alterations in mouse ovaries. Int J Mol Sci.
- Ravanos K, Monastra G, Pavlidou T, et al. (2017). Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality? J Assist Reprod Genet.
- Bhide P, Pundir J, Gudi A, et al. (2019). The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI. Acta Obstet Gynecol Scand.
- Laganà AS, Garzon S, Casarin J, et al. (2018). Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab.
- Larner J, Price JD, Heimark D, et al. (2003). Isolation, structure, synthesis, and bioactivity of a novel putative insulin mediator. J Med Chem.
Shop WHYZ
- WHYZ Myo-Inositol Powder, pure, unflavored myo-inositol. No fillers, no additives. Available at WHYZ.com.
Related Guides
Last reviewed: April 11, 2026 by the WHYZ Editorial Team. This article is for informational purposes only and does not constitute medical advice. Consult a healthcare provider before starting any supplement.